Associate Principal AI Engineer - Mathematical Optimisation
AstraZeneca1 day ago
Cambridge, United KingdomStaff+
Responsibilities
- Design and develop end-to-end AI solutions using mathematical optimisation, modelling, and simulation.
- Build, maintain, and support robust, accurate, and reliable AI and optimisation solutions at scale.
- Visualise complex datasets and model outputs using front-end technologies.
- Collaborate with optimisation engineers, AI engineers, scientists, software developers, engineering teams, and product teams.
- Translate complex business challenges into well-defined engineering problems.
- Contribute to interactive applications and dashboarding solutions where needed.
- Promote strong software development and deployment practices across the organisation.
Requirements
- Demonstrable experience developing operations research solutions for complex real-world problems.
- Experience with mathematical optimisation software such as CPLEX, Gurobi, SCIP, or OR-Tools.
- Experience with heuristic and meta-heuristic algorithms.
- Working knowledge of optimisation, simulation, statistical concepts, and LLM tools.
- Good software development and deployment experience, ideally including Python.
- Experience translating complex business challenges into engineering problems.
- MSc or higher.
- Desirable experience in control, robotics, AI tool deployment, interactive applications, full-stack applications, or dashboarding.
Benefits
- Competitive salary and excellent benefits.
- Hybrid working arrangement with an average minimum of three days per week in the office in Cambridge, UK.
- Inclusive workplace with reasonable adjustments and accommodations available during the recruitment process.
- Opportunity to work on technology supporting the development of life-changing medicines.
Tech Stack
Categories
About AstraZeneca
AstraZeneca is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines for patients and healthcare systems. Its portfolio spans oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases (expanded by the 2021 acquisition of Alexion). Founded in 1999 and headquartered in Cambridge, UK, it is a public company listed on the London Stock Exchange and Nasdaq, generating revenue primarily from drug sales and partnerships.